January 23, 2023 - The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa),
manufactured by the biotechnology company BeiGene, which is a next-generation BTK inhibitor
January 23, 2023 - TheracosBio has announced that the U.S. Food and Drug Administration (FDA) has approved Brenzavvy (bexagliflozin), an oral sodium-glucose
January 13, 2023 – The FDA signed the Agreement on Mutual Recognition between the Swiss Confederation and the U.S. Relating to Pharmaceutical Good Manufacturing Practice.
January 12, 2023 - The FDA has approved a label update for Rybelsus (semaglutide) tablets 7 mg or 14 mg, allowing use as a first-line treatment option for adults